AnaCardio selected as finalist at the J.P. Morgan Asset Management: Life Sciences Innovation Summit
Stockholm, Sweden, April 4 , 2024 AnaCardio, a Swedish clinical-stage biopharmaceutical company focused on developing novel contractile agents to treat patients with heart failure, announced